Josep M Domingo-Domenech, MD, PhD
- ASSOCIATE PROFESSOR | Pathology
Research Topics:Cancer, Cancer Genetics, Drug Design and Discovery, Drug Resistance, Gene Regulation, Metastasis, Oncogenes, Prostate
Multi-Disciplinary Training AreasCancer Biology [CAB], Genetics and Genomic Sciences [GGS]
MD, University of Barcelona
Residency Medical Oncology, Hospital Clinic Barcelona
Master Healthcare Services Management, ESADE Bussiness School
PhD, University of Barcelona
Postdoctoral, Columbia University
The main focus of my group is to assess the molecular and cellular pathogenesis of cancer, primarily in prostate and bladder tumors. We use in vitro and in vivo mouse experimental models together with patient datasets to functionally dissect the genes and pathways involved in the initiation, therapy response and aggressiveness of cancer. In addition, we are investigating the cellular heterogeneity of tumors to identify the molecular pathways that allow a subset of cancer cells survive standard therapy. My research program comprehensively integrates experimental data using computational tools to develop novel anti-tumor therapeutic approaches and determine new molecular surrogates of clinical outcome.
Williams E, Rodriguez-Bravo V, Chippada-Venkata U, de la Iglesia J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp 2015 Oct; 20.
Vidal S, Rodriguez-Bravo V, Quinn A, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak D, Dudley J, Rabadan R, Silva J, Hoshida Y, Lowe S, Cordon-Cardo C, Domingo-Domenech J. A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 2015 Feb; 27.
Vidal S, Quinn A, de la Iglesia J, Bonal D, Rodriguez-Bravo V, Firpo-Betancourt A, Cordon-Cardo C, Domingo-Domenech J. Isolation of cancer stem cells from human prostate cancer samples. J Vis Exp 2014 Mar; 14.
Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2013 Oct;.
Galsky MD, Domingo-Domenech J. Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clinical advances in hematology & oncology : H&O 2013 Feb; 11(2).
Jia AY, Castillo-Martin M, Domingo-Domenech J, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C. A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. The American journal of pathology 2013 Apr; 182(4).
Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer cell 2012 Sep; 22(3).
Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. The Journal of urology 2011 Nov; 186(5).
Domingo-Domènech J, Pippa R, Tápia M, Gascón P, Bachs O, Bosch M, Benson MC, McKiernan JM, Cordon-Cardo C. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast cancer research and treatment 2008 Nov; 112(1).
Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A, Codony J, Gascon P, Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008 Feb; 19(2).
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Sep; 12(18).